ClinicalTrials.gg
RecruitingNCT06274593OGAUpdated Jun 24, 2026

Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma

An observational study in Glaucoma, sponsored by Nantes University Hospital. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Nantes University Hospital · Observational

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Glaucoma with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Glaucoma · France.

Planned enrollment
13th of 16
50 · median 120
Started
2024
with 2 others
Observational
16 of 54
3 open now
Primary completion
2027-04
later than 2 of 10 live
Registered
47th of 54
by date

Among the 54 studies in Glaucoma with a site in France, this one is the 13th largest by planned enrollment of the 16 observational ones that give a count, is one of 3 that started in 2024, is one of 16 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 47th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

10 of the 54 studies in Glaucoma with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Glaucoma with a site in France, or all of them as a file.
02

Study summary

Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness.

To date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma.

The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).

Read the detailed description

Glaucoma is a chronic disease of the optic nerve characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second-leading cause of blindness after cataracts and the leading cause of irreversible blindness.

The pathophysiology and loss of retinal ganglion cells are partly explained by 2 main theories:

  • biomechanical theory, which takes into account the forces and deformations of the optic nerve linked to IOP (intraocular pressure) and to the anatomy of the optic nerve head, particularly at the level of the cribriform plate (a zone of deformable weakness surrounded by a rigid scleral shell),
  • the vascular theory, explained by abnormalities in the vascularization of the optic nerve and retina.

Optical coherence tomography angiography (OCTa) is a relatively new imaging method that has been on the market for around ten years.

It is a non-invasive method that provides qualitative and quantitative information on retinal vascularization and the optic nerve head. The movement of red blood cells is used as a contrast medium to differentiate blood vessels from static tissue.

In glaucoma, changes in the peripapillary vascular plexus (around the optic nerve head) can be observed and are topographically correlated with visual field and peripapillary nerve fiber deficits.

One of the challenges in monitoring glaucoma patients lies in detecting the progression of the disease with the help of various complementary examinations, including the visual field, peripapillary nerve fiber OCT (RNFL), and more recently, OCTa.

The visual field is used to detect areas of vision deficit (peripheral or sometimes central), known as scotomas, and to monitor their evolution. RNFL OCT measures the thickness of the optic nerve (in micrometers) in its various quadrants. OCTa measures vascular density, also by quadrant, around the optic nerve head.

A deterioration in any of these parameters can help guide therapeutic management by modifying medical treatment or proposing surgery to lower intraocular pressure in the affected eye.

One of the difficulties in monitoring glaucoma patients lies in detecting optic nerve thinning in patients with advanced optic nerve damage. It is now well known that at an advanced stage of the disease, measurement of optic nerve thickness on RNFL OCT can reach a "floor" effect: residual non-neuronal tissue limits the usefulness of detecting changes in neuronal tissue, and disease progression can only be detected by visual field monitoring.

Vascular density measured on OCTa appears to reach a plateau effect in a delayed manner compared with measurements obtained on peripapillary OCT (RNFL) and could enable better monitoring of disease progression in patients with advanced glaucoma.

Indeed, a new objective follow-up criterion measured with OCTa in clinical practice for patients with uninterpretable OCTrnfl would be a valuable tool for assessing the rate of glaucoma progression in these patients and thus defining the rate of monitoring and the decision to intensify treatment in the event of progression. This is all the more important as the treatments available for glaucoma are sometimes invasive (drainage devices, surgery, etc.). Assessing the benefit-risk balance therefore requires objective data for these patients.

To date, to our knowledge, there are no studies analyzing the evolution of OCT angiography in glaucoma patients.

The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • glaucoma
  • OCTa
  • OCTrnfl
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients followed at Nantes University Hospital for advanced glaucoma (MD>10dB in visual field) who had peripapillary angiography OCT, OCTrnfl and visual field at their follow-up consultation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 and over
  • Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital
  • mean visual field deficit (MD) >10dB

Exclusion criteria

Exclusion Criteria:

  • Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...)
  • PPR (retinal PanPhotocoagulation), retinal cerclage
  • Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa)
  • AMD and other macular pathologies that can lead to central visual field deficits
  • Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract)
  • Loss of fixation point preventing visual field formation Pregnant or breast-feeding women
  • Protected adults under guardianship or curatorship
  • with unreliable visual fields (false positives and false negatives > 33%)
  • with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • DeviceOCT

    Peripapillary angiography (OCT) at baseline and each year during 3 year

06

What researchers measure

Primary outcomes

  1. Compare the progression of vascular density (VD) in advanced glaucoma patients.

    Progression of peripapillary vascular density (VD) (in percent) per sector (8 sectors) with 3-year follow-up.

    Time frame: 3 year

  2. Compare the progression of peripapillary retinal nerve fiber (RNFL) thickness) in advanced glaucoma patients.

    Progression of peripapillary nerve fiber thickness (RNFL, in µm) per sector (8 sectors) with 3-year follow-up.

    Time frame: 3 year

  3. Compare the progression of visual field in advanced glaucoma patients.

    Progression of visual field deficit (in dB) by sector (8 sectors) with 3-year follow-up

    Time frame: 3 year

Secondary outcomes

  1. CV-OCTrnfl correlation study and CV-OCTa correlation study on measurements made at inclusion and on measurements made during follow-up

    Study of the correlation between CV-OCTrnfl and correlation between CV-OCTa (mean in µm)

    Time frame: 3 years

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

Of 110 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 36 months is below that.

Counting every sponsor, half of 134 studies reached it within 31 months; a quarter within 12 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 23, 2024
StartActual
Apr 27, 2024
Primary completionEst.
Apr 27, 2027
CompletionEst.
Sep 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06274593
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Apr 27, 2024
Primary completion
Apr 27, 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Jean-Baptiste Ducloyer, M.D
Contact
jeanbatiste.ducloyer@chu-nantes.fr
02 40 08 34 01
Isabelle Orignac, M.D
Contact
isabelle.orignac@chu-nantes.fr
02 40 08 34 01

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion